KBC Group
IMVT icon

KBC Group’s Immunovant IMVT Stock Holding History

KBC Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87K Hold
3,490
– – ﹤0.01% 1408
2025
Q4 		$89K Hold
3,490
– – ﹤0.01% 1362
2025
Q3 		$56K Buy
3,490
+1,683
+93% +$27.2K ﹤0.01% 1607
2025
Q2 		$29K Sell
1,807
-1,735
-49% -$26.2K ﹤0.01% 1702
2025
Q1 		$61K Buy
3,542
+443
+14% +$9.27K ﹤0.01% 1728
2024
Q4 		$77K Buy
3,099
+1,163
+60% +$33K ﹤0.01% 1693
2024
Q3 		$55K Buy
1,936
+612
+46% +$18.1K ﹤0.01% 1664
2024
Q2 		$35K Hold
1,324
– – ﹤0.01% 1779
2024
Q1 		$43K Hold
1,324
– – ﹤0.01% 1632
2023
Q4 		$56K Buy
1,324
+406
+44% +$14.9K ﹤0.01% 1443
2023
Q3 		$35K Buy
+918
New +$20.8K ﹤0.01% 1706

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

KBC Group's IMVT Position: Q1 2026 in Review

KBC Group held its Immunovant (IMVT) position steady in Q1 2026 at 3,490 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #1408.

KBC Group first reported a position in IMVT in Q3 2023 and has held it in 11 quarters since. The position peaked at $89K in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • KBC Group held 3,490 shares of Immunovant worth $87K as of Q1 2026.
  • KBC Group left its Immunovant share count unchanged in Q1 2026.
  • Immunovant made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1408 holding.
  • KBC Group first reported a position in Immunovant in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's Immunovant position peaked at $89K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.